Background

Acute coronary syndrome comprises of about 20–23% of patients presenting at emergency department accounts for increasing mortality and morbidity world wide . Along with ECG and other clinical parameters, cardiac biomarkers do have an important role in the early diagnosis and management of patient with ACS. Ischemia modified albumin is one of the recently identified ischemic biomarker approved by U.S food and drug administration .

Aim and objective To measure IMA and CKMB levels in the patient with ACS.The role of IMA as an early marker in diagnosis of ACS when compare with CKMB.

Materials and methods

Study group includes 50 patients with ACS and 50 age and sex matched healthy controls. Serum IMA levels measured by cobalt binding assay method measured colorimetrically.serum albumin and creatinine kinase (CK–MB) measured by bromocresol green ,  immune inhibition method respectively.

Results  Serum IMA levels increased in early hours of ACS  (mean =115.05±17.55) when compared to healthy controls.

Conclusion  Increased  serum IMA levels in early hours of ACS can be used in the diagnosis of ACS along with ECG and other biomarker CKMB.